Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – August 14, 2013 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA
Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:
1. Call To Order
   A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:
2. Public Comment Forum
   A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:
3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.
   A. July 10, 2013 DUR Minutes – Vote
   B. July 10, 2013 DUR Recommendation Memorandum

Items to be presented by Dr. Le & Dr. Holderread, Dr. Muchmore, Chairman:
4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.
   A. Medication Coverage Activity for July 2013
   B. Pharmacy Help Desk Activity for July 2013
   C. SoonerCare Atypical Rx Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:
5. Action Item – Authorize Fulyzaq™ – See Appendix C.
   A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:
6. Action Item – Vote to Prior Authorize Vecamyl™ – See Appendix D.
   A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:
7. Action Item – Annual Review of ADHD Medications and 30 Day Notice to PA
   Quillivant XR™ – See Appendix E.
   A. Current Authorization Criteria
   B. Utilization of Stimulants
   C. Prior Authorization Review
   D. Market News and Updates
   E. Product Summary
   F. COP Recommendations
   G. Utilization Details
   H. Product Details
8. Action Item – Annual Review of Atypical Antipsychotics Appendix F.
   A. Current Authorization Criteria
   B. Utilization of Atypical Antipsychotics
   C. Prior Authorization Review
   D. Market News and Updates
   E. Utilization Details
   F. COP Recommendations
   G. Utilization Details

9. 30 Day Notice to Prior Authorize Tysabri® – See Appendix G.
   A. Summary
   B. Utilization of Tysabri®
   C. COP Recommendations
   D. Product Details

10. 30 Day Notice to Prior Authorize Diclegis® – See Appendix H.
    A. Summary
    B. COP Recommendations
    C. Product Details

    A. Current Authorization Criteria
    B. Utilization of Synagis®
    C. Prior Authorization Review
    D. COP Recommendations

13. FDA and DEA Updates – See Appendix J.

14. Future Business
    A. Annual Reviews
    B. New Product Reviews

15. Adjournment